All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

# Final Appraisal Recommendation

**Advice No: 0315 – February 2015**

## Aflibercept (Zaltrap®▼) 25 mg/ml concentrate for solution for infusion

## Submission by Sanofi

### Recommendation of AWMSG

**Aflibercept (Zaltrap®▼) is not recommended for use within NHS Wales in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy for the treatment of adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin containing regimen. The case for cost-effectiveness has not been proven.**

**Refer to the NICE Technology Appraisal Guidance (TA307) which will continue to apply within NHS Wales**

**Additional note(s):**

- AWMSG appraised the above medicine in light of a negative recommendation by the National Institute for Health and Care Excellence (NICE) and the subsequent availability of this medicine via a commissioning route within NHS England.
- Additional evidence above that considered by NICE was submitted by the marketing authorisation holder, Sanofi-Aventis Ltd.
- There are several uncertainties and limitations in the economic model provided in the company's submission.
- AWMSG did not apply criteria for appraising life-extending, end-of-life medicines to aflibercept (Zaltrap®▼) for the indication under consideration as there was insufficient evidence that the three month life extension criterion was fulfilled.
- Patients who are currently being treated with aflibercept (Zaltrap®▼) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.
- In light of AWMSG's recommendation, NICE's advice is extant.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 456), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

| | |
|---|---|
| Marketing authorisation holder on first issue | Sanofi Aventis Ltd |
| Date of first issue | February 2015 |
| Last reviewed | June 2018 |